Research Article

Yi-Hong Zhou, Huan Li, Yuan-Yuan Qin, Xiao-Feng Yan, Yan-Qiu Lu, Hong-Lan Liu, Si-Kuan Ye, Yan Wan, Lu Zhang, Vijay Harypursat, Yaokai Chen*

Predictive factors of progression to severe COVID-19

https://doi.org/10.1515/med-2020-0184
received May 13, 2020; accepted June 14, 2020

Abstract

Aim – Early diagnosis and treatment are crucial for the survival of severe Coronavirus Disease 2019 (COVID-19) patients, but data with regard to risk factors for disease progression from milder COVID-19 to severe COVID-19 remain scarce.

Methods – We conducted a retrospective analysis on 116 patients.

Results – Three factors were observed to be independently associated with progression to severe COVID-19 during 14 days after admission: (a) age 65 years or older (hazard ratio [HR] = 8.456; 95% CI: 2.706–26.426); (b) creatine kinase (CK) ≥ 180 U/L (HR = 3.667; 95% CI: 1.253–10.733); and (c) CD4+ T-cell counts <300 cells/µL (HR = 4.695; 95% CI: 1.483–14.856). The difference in rates of severe COVID-19 development was found to be statistically significant between patients aged 65 years or older (46.2%) and those younger than 65 years (90.2%), between patients with CK ≥ 180 U/L (55.6%) and those with CK < 180 U/L (91.5%), and between patients with CD4+ T-cell counts <300 cells/µL (53.8%) and those with CD4+ cell counts ≥300 cells/µL (83.2%).

Conclusions – Age ≥ 65 years, CK ≥ 180 U/L, and CD4+ T-cell counts <300 cells/µL at admission were risk factors independently associated with disease progression to severe COVID-19 during 14 days after admission and are therefore potential markers for disease progression in patients with milder COVID-19.

Keywords: Coronavirus, SARS-CoV-2, COVID-19, predictive, progression

1 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in Wuhan, the provincial capital of Hubei Province, China, in December 2019 [1]. The virus is known to spread with ease from person to person among close contacts [2] and may cause an acute respiratory illness, which has been named Coronavirus Disease 2019 (COVID-19). Most patients with SARS-CoV-2 infection develop mild to moderate upper respiratory tract symptoms, whereas others may develop severe respiratory distress, systemic sepsis, septic shock, and death [3-5]. Some patients present with fever and respiratory symptoms such as cough and shortness of breath, and others may present with gastrointestinal symptoms including diarrhea, vomiting, and abdominal pain [6]. In addition, some atypical symptoms such as altered mental status, symptoms of stroke, and olfactory and gustatory dysfunctions have been described [7,8]. Although patients with mild to moderate COVID-19 usually have a good prognosis, severe COVID-19 is associated with high mortality.

Early diagnosis and treatment are crucial for the survival of severe COVID-19 patients. As most patients who develop severe COVID-19 start with mild symptoms and later progress to severe disease, it is imperative to identify potential risk factors for disease progression in this population. This may help healthcare providers timeously identify patients with disease progression potential, thus facilitating early diagnosis and treatment of severe COVID-19. However, data with regard to potential risk factors for disease progression from mild or moderate COVID-19 to severe COVID-19 outside Wuhan remain scarce in the published literature and therefore warrant further investigation.
Our infectious disease hospital began admitting COVID-19 patients from January 24, 2020, and over 200 COVID-19 patients had been admitted up until February 20, 2020. The majority were diagnosed with mild or moderate COVID-19 at admission. However, a subgroup of these milder COVID-19 patients progressed to severe COVID-19 during their hospital stay, whereas others stabilized and recovered. In the present study, we retrospectively analyzed the clinical data of patients admitted to our hospital with milder COVID-19, including those who progressed to severe disease after admission. Our objective was to investigate the presence of potential risk factors associated with disease severity progression in the natural history of COVID-19.

2 Material and methods

2.1 Ethics, consent, and permissions

This study was approved by the Ethics Committee of Chongqing Public Health Medical Center (2020-003-01-KY). Informed consent was waived as all data were retrospective and were collected anonymously.

2.2 Patient enrollment and data collection

We included all patients aged 18 or older who had a confirmed diagnosis of mild or moderate COVID-19, who were admitted to Chongqing Public Health Medical Center, China, from January 24, 2020, to February 7, 2020. We transcribed demographics, epidemiological information, clinical manifestations, and clinical outcomes of eligible patients from the electronic hospital medical record system onto case record forms. Laboratory test results including blood gas analysis, hematological analysis, C-reactive protein, coagulation tests, myocardial enzymes, clinical chemistry, and lymphocyte subsets were also extracted from the records and recorded.

Patients exhibiting one or more of the following conditions were classified as having severe COVID-19: (a) respiratory distress (≥30 breaths/min); (b) oxygen saturation ≤93% at rest; (c) arterial partial pressure of oxygen (PaO₂)/fraction of inspiration O₂ (FiO₂) ≤300 mmHg (1 mmHg = 0.133 kPa); (d) respiratory failure requiring mechanical ventilation; (e) development of septic shock; and (f) critical organ failure requiring ICU care. Patients not meeting the aforementioned criteria were classified as mild or moderate COVID-19 cases and referred to as “milder” cases as a stratification category to clearly differentiate between milder and severe cases of COVID-19 in our data analysis.

2.3 Statistical analysis

All analyses were performed using Statistical Package for the Social Sciences software, Version 19.0 (IBM SPSS Statistics, Chicago, IL, USA). Categorical variables were described as frequency rates and percentages and compared via the Chi-squared test or the Fisher exact test as appropriate. Continuous variables were described using mean, median, and interquartile range (IQR) values. Mean values for continuous variables were compared using independent group t-tests when the data were normally distributed; otherwise, the Mann–Whitney test was used. Statistical significance was assumed when p-values less than 0.05 were calculated. Furthermore, time to developing severe COVID-19 was analyzed over the duration of 14 days of hospitalization by the Kaplan–Meier method. The hypothesis test was two tailed, with a p ≤ 0.05 indicative of statistical significance. Cox regression was applied to estimate the unadjusted hazard ratios (HRs) of risk factors for disease progression during 14 days of hospitalization, and adjusted HRs were identified by using a forward stepwise approach.

3 Results

3.1 Patient characteristics

A total of 130 patients with mild or moderate COVID-19 were admitted to our hospital from January 24, 2020, to February 7, 2020. After excluding four patients younger than 18 years and ten patients diagnosed with severe COVID-19 at admission, a total of 116 patients were included for the analysis in this study. Of them, 17 patients (14.7%) eventually developed severe disease, while 99 patients (85.3%) did not meet the criteria for diagnosis of severe COVID-19 during 14 days of hospitalization.

As depicted in Table 1, patients who developed severe COVID-19 were significantly older (59 years [IQR,
Table 1: Patient characteristics at hospital admission

| Characteristics                        | Total (n = 116) | No progression to severe COVID-19 (n = 99) | Progression to severe COVID-19 (n = 17) | p         |
|----------------------------------------|----------------|-------------------------------------------|----------------------------------------|-----------|
| Medical age, median (IQR), years       | 46 (36–56)     | 41 (35–54)                                | 59 (50–70)                             | <0.001    |
| Gender, n (%)                          |                |                                           |                                        |           |
| Male                                   | 59             | 51 (51.5)                                 | 8 (47.1)                               | 0.734     |
| Female                                 | 57             | 48 (48.5)                                 | 9 (52.9)                               |           |
| Married, n (%)                         |                |                                           |                                        |           |
| Yes                                    | 98             | 82 (82.8)                                 | 16 (94.1)                              | 0.409     |
| No                                     | 18             | 17 (17.2)                                 | 1 (5.9)                                |           |
| Smoking, n (%)                         |                |                                           |                                        |           |
| Yes                                    | 21             | 17 (17.2)                                 | 4 (23.5)                               | 0.773     |
| No                                     | 95             | 82 (82.8)                                 | 13 (76.5)                              |           |
| BMI                                     | 23.69 ± 2.92   | 23.6 ± 2.92                               | 24.11 ± 2.94                           | 0.527     |
| Symptoms at admission, n (%)           |                |                                           |                                        |           |
| Yes                                    | 106            | 90 (90.9)                                 | 16 (94.1)                              | 1.000     |
| No                                     | 10             | 9 (9.1)                                   | 1 (5.9)                                |           |
| History of stay in Wuhan, n (%)        |                |                                           |                                        |           |
| Yes                                    | 37             | 34 (34.3)                                 | 3 (17.6)                               | 0.172     |
| No                                     | 79             | 65 (65.7)                                 | 14 (82.4)                              |           |
| Diabetes, n (%)                        |                |                                           |                                        |           |
| Yes                                    | 9              | 7 (7.1)                                   | 2 (13.3)                               | 0.859     |
| No                                     | 107            | 92 (92.9)                                 | 15 (86.7)                              |           |
| Hypertension, n (%)                    |                |                                           |                                        |           |
| Yes                                    | 14             | 11 (11.1)                                 | 3 (17.6)                               | 0.718     |
| No                                     | 102            | 88 (88.9)                                 | 14 (82.4)                              |           |
| Time from symptom onset to hospital admission, median (IQR), d | 4 (2–7) | 4 (2–7) | 5 (4–7) | 0.224 |
| Time from symptom onset to severe COVID-19, median (IQR), d | – – | – | 12 (10–15) | – |
| Time from hospital admission to severe COVID-19, median (IQR), d | – – | – | 6 (4–9) | – |

BMI: body mass index; IQR: interquartile range.

50–70] vs 41 years [IQR, 35–54], p < 0.001) compared with those who did not develop severe COVID-19. In the 17 patients who went on to develop severe COVID-19 during 14 days of hospitalization, the median duration from the symptom onset to the diagnosis of severe COVID-19 was 12 days (IQR, 10–15), and the median duration from hospital admission to diagnosis of severe COVID-19 was 6 days (IQR, 4–9).

3.2 Comparison of clinical manifestations between the two groups

In our cohort of 116 patients, fever was the most common symptom at illness onset, occurring in 67.2% of patients in our cohort, followed by cough (59.5%), sputum production (37.9%), fatigue (27.6%), and anorexia (23.3%). In addition, some patients presented with atypical symptoms including heart palpitations (0.9%), xerostomia (0.9%), hemoptysis (0.9%), hyposmia (0.9%), and low back pain (1.7%). There were no significant differences in clinical symptoms between patients who developed severe COVID-19 and those who did not during 14 days of hospitalization after admission in our cohort (Table 2).

3.3 Comparison of laboratory test results between the two groups

Compared with patients who had milder COVID-19, those who developed severe COVID-19 after admission had significantly lower lymphocyte counts, platelet counts, estimated glomerular filtration rates (eGFRs), CD4+ T-cell counts, CD8+ T-cell counts, and PaO₂/FiO₂ ratios, and significantly higher C-reactive protein levels, lactate dehydrogenase levels, aspartate transaminase levels, and beta 2-microglobulin levels (Table 3).
Table 2: Clinical manifestations of patients with COVID-19 at hospital admission

| Signs and symptoms | Total | No progression to severe COVID-19 | Progression to severe COVID-19 | p |
|--------------------|-------|----------------------------------|-------------------------------|---|
| Fever, n (%)       |       |                                  |                               |   |
| Yes                | 78    | 67 (67.7)                        | 11 (64.7)                     | 0.809 |
| No                 | 38    | 32 (32.2)                        | 6 (35.3)                      |   |
| Rigors, n (%)      |       |                                  |                               |   |
| Yes                | 7     | 7 (7.1)                          | 0 (0.0)                       | 0.562 |
| No                 | 109   | 92 (92.9)                        | 17 (100)                      |   |
| Fatigue, n (%)     |       |                                  |                               |   |
| Yes                | 32    | 28 (88.3)                        | 4 (23.5)                      | 0.911 |
| No                 | 84    | 71 (81.7)                        | 13 (76.5)                     |   |
| Cough, n (%)       |       |                                  |                               |   |
| Yes                | 69    | 58 (61.1)                        | 11 (64.7)                     | 0.635 |
| No                 | 47    | 41 (41.4)                        | 6 (35.3)                      |   |
| Dyspnea, n (%)     |       |                                  |                               |   |
| Yes                | 3     | 1 (1.0)                          | 2 (11.7)                      | 0.056 |
| No                 | 113   | 98 (99.0)                        | 15 (88.2)                     |   |
| Sputum, n (%)      |       |                                  |                               |   |
| Yes                | 44    | 36 (81.8)                        | 8 (47.1)                      | 0.401 |
| No                 | 72    | 63 (86.6)                        | 9 (52.9)                      |   |
| Sore throat, n (%) |       |                                  |                               |   |
| Yes                | 20    | 17 (85.0)                        | 3 (15.0)                      | 1.000 |
| No                 | 96    | 82 (85.4)                        | 14 (14.6)                     |   |
| Xerostomia, n (%)  |       |                                  |                               |   |
| Yes                | 1     | 1 (1.0)                          | 0 (0.0)                       | 1.000 |
| No                 | 115   | 98 (99.0)                        | 17 (100.0)                    |   |
| Hemoptysis, n (%)  |       |                                  |                               |   |
| Yes                | 1     | 0 (0.0)                          | 1 (5.9)                       | 0.147 |
| No                 | 115   | 99 (100.0)                       | 16 (94.1)                     |   |
| Palpitations, n (%)|       |                                  |                               |   |
| Yes                | 1     | 0 (0.0)                          | 1 (5.9)                       | 0.147 |
| No                 | 115   | 99 (100.0)                       | 16 (94.1)                     |   |
| Myalgia, n (%)     |       |                                  |                               |   |
| Yes                | 10    | 9 (90.0)                         | 1 (10.0)                      | 1.000 |
| No                 | 106   | 89 (90.8)                        | 14 (9.2)                      |   |
| Arthralgia, n (%)  |       |                                  |                               |   |
| Yes                | 4     | 3 (75.0)                         | 1 (25.0)                      | 0.474 |
| No                 | 112   | 96 (86.0)                        | 14 (14.0)                     |   |
| Low back pain, n (%)|      |                                  |                               |   |
| Yes                | 2     | 2 (100)                          | 0 (0.0)                       | 1.000 |
| No                 | 114   | 97 (83.6)                        | 17 (16.4)                     |   |
| Abdominal pain, n (%)|    |                                  |                               |   |
| Yes                | 4     | 3 (75.0)                         | 1 (25.0)                      | 0.474 |
| No                 | 112   | 96 (86.0)                        | 14 (14.0)                     |   |
| Nausea and vomiting, n (%)|  |                                  |                               |   |
| Yes                | 4     | 3 (75.0)                         | 1 (25.0)                      | 0.474 |
| No                 | 112   | 96 (86.0)                        | 14 (14.0)                     |   |
| Diarrhea, n (%)    |       |                                  |                               |   |
| Yes                | 10    | 9 (90.0)                         | 1 (10.0)                      | 1.000 |
| No                 | 106   | 90 (90.9)                        | 16 (9.1)                      |   |
| Anorexia, n (%)    |       |                                  |                               |   |
| Yes                | 27    | 22 (81.5)                        | 5 (18.5)                      | 0.736 |
| No                 | 89    | 77 (86.5)                        | 12 (13.5)                     |   |

Table 2: Continued

| Signs and symptoms | Total | No progression to severe COVID-19 | Progression to severe COVID-19 | p |
|--------------------|-------|----------------------------------|-------------------------------|---|
| Headache, n (%)    |       |                                  |                               |   |
| Yes                |       |                                  |                               |   |
| No                 |       |                                  |                               |   |

| Signs and symptoms | Total | No progression to severe COVID-19 | Progression to severe COVID-19 | p |
|--------------------|-------|----------------------------------|-------------------------------|---|
| Yes                | 15    | 12 (79.3)                        | 3 (20.7)                      | 0.813 |
| No                 | 101   | 87 (86.1)                        | 14 (13.9)                     |   |
| Dizziness, n (%)   |       |                                  |                               |   |
| Yes                | 14    | 11 (78.6)                        | 3 (21.4)                      | 0.718 |
| No                 | 102   | 88 (86.3)                        | 14 (13.7)                     |   |
| Hyposmia, n (%)    |       |                                  |                               |   |
| Yes                | 1     | 1 (100)                          | 0 (0.0)                       | 1.000 |
| No                 | 115   | 98 (85.8)                        | 17 (14.2)                     |   |
| Asymptomatic, n (%)|       |                                  |                               |   |
| Yes                | 10    | 9 (90.0)                         | 1 (10.0)                      | 1.000 |
| No                 | 106   | 90 (89.7)                        | 16 (10.3)                     |   |
| Moist rales, n (%) |       |                                  |                               |   |
| Yes                | 9     | 6 (66.7)                         | 3 (33.3)                      | 0.246 |
| No                 | 107   | 93 (87.4)                        | 14 (12.6)                     |   |
| Median pulse, mean ± SD, beats/min | 90.06 ± 13.293 | 90.40 ± 13.065 | 0.665 |
| Median systolic blood pressure, median (IQR), mm Hg | 127.25 ± 15.148 | 126.69 ± 15.116 | 0.336 |

SD: standard deviation.

3.4 Comparison of therapeutic interventions between the two groups

The proportion of antibiotic use in patients who developed severe COVID-19 was significantly higher than in patients who did not develop severe COVID-19 (35.3% vs 10.1%, p = 0.016) during 14 days of hospitalization. However, we found no statistical correlation in the relative use of lopinavir/ritonavir, ribavirin, and traditional Chinese medicine between the two groups of patients, as presented in Table 4.

3.5 Independent risk factors for progression to severe COVID-19

All variables with a p ≤ 0.1 in the univariate analysis, other than lymphocyte counts, were included in a Cox proportional hazards model and adjusted for symptoms at admission, ribavirin use, lopinavir/ritonavir use, comorbid diabetes, and comorbid hypertension. We did
Table 3: Laboratory findings of patients with COVID-19 at hospital admission

| Laboratory values                  | Number of patients | Total       | No progression to severe COVID-19 | Progression to severe COVID-19 | p       |
|------------------------------------|--------------------|-------------|-----------------------------------|--------------------------------|---------|
| White blood cell count (<10^9/L)   | 115                | 4.84 (3.87–5.84) | 4.81 (3.85–6.05) | 4.96 (3.89–5.54) | 0.741   |
| Neutrophil count (<10^9/L)         | 114                | 2.87 (2.00–3.39)  | 2.77 (1.98–3.95) | 3.41 (2.55–4.12) | 0.310   |
| Lymphocyte count (<10^9/L)         | 115                | 1.32 (1.06–1.76)   | 1.45 (1.18–1.78) | 1.03 (0.74–1.28) | 0.002   |
| Platelet count (<10^9/L)           | 115                | 163 (128–212)      | 169.5 (132.25–216.00) | 136 (96–174) | 0.029   |
| Hemoglobin (g/L)                   | 115                | 136 (125–147)       | 137.5 (124.75–148) | 128 (122–139) | 0.117   |
| C-reactive protein (mg/L)          | 112                | 9.36 (2.96–26.26)   | 7.99 (2.87–21.57) | 25.55 (10.03–70.17) | 0.002   |
| D-dimer (mg/L)                     | 112                | 0.16 (0.10–0.26)    | 0.14 (0.09–0.25) | 0.21 (0.12–0.3) | 0.157   |
| CK (U/L)                           | 112                | 74.5 (49.5–128)     | 70.5 (47.5–108.25) | 149 (53.25–299) | 0.088   |
| LDH (U/L)                          | 116                | 195 (164–251)       | 190 (163–237) | 273 (185.5–310.5) | 0.003   |
| ALT (U/L)                          | 116                | 21 (13.25–31.75)    | 21 (13–31) | 21 (15–52) | 0.290   |
| AST (U/L)                          | 116                | 24 (19–31)            | 22 (18–28) | 33 (25–46.5) | 0.002   |
| Albumin (g/L)                      | 116                | 42.236 ± 3.657      | 42.273 ± 3.544 | 40.613 ± 3.649 | 0.095   |
| Total bilirubin (μmol/L)           | 116                | 13.05 (9.625–19.150) | 12.7 (9.6–17.8) | 17.6 (11.2–22.6) | 0.102   |
| Creatinine (μmol/L)                | 115                | 70.1 (59.3–84)       | 69.65 (58.08–83.55) | 70.1 (61–89.35) | 0.555   |
| Beta 2-microglobulin (mg/L)        | 114                | 2.57 (2.15–3.05)     | 2.51 (2.14–2.95) | 3.34 (2.53–3.79) | 0.004   |
| eGFR                               | 115                | 98.36 ± 18.83       | 100.51 ± 18.177 | 83.94 ± 18.164 | 0.006   |
| CD4+ T-cell counts (cells/µL)      | 85                  | 424 (264–594)       | 478 (322–606) | 243.5 (223–290.75) | <0.001  |
| CD8+ T-cell counts (cells/µL)      | 83                  | 316 (207–459)       | 359 (231–490) | 159.5 (126–313.25) | 0.003   |
| CD4+ T-cell counts/CD8+ cell counts| 83                  | 1.31 (0.98–1.75)     | 1.36 (1.01–1.73) | 1.13 (0.76–1.97) | 0.403   |
| PaO₂/FiO₂ (mmHg)                   | 74                  | 416.28 (365.48–455.54) | 419 (376.19–471.42) | 366.67 (321.67–413.14) | 0.005   |

LDH: lactate dehydrogenase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; eGFR: estimated glomerular filtration rate; PaO₂: partial pressure of oxygen; PaO₂/FiO₂: partial arterial oxygen concentration/inspired oxygen fraction.

not include lymphocyte counts in this model to avoid the possible multicollinearity effect on CD4+ T-cell counts.

Three factors were found to be independently associated with progression to severe COVID-19 (Table 5) during 14 days of hospitalization after admission, and these factors are as follows: (a) age 65 years or older (HR = 8.456; 95% CI: 2.706–26.426; p < 0.001); (b) creatinine (CK) ≥ 180 U/L (HR = 3.667; 95% CI: 1.253–10.733; p = 0.018); and (c) CD4+ T-cell counts <300 cells/µL (HR = 4.695; 95% CI: 1.483–14.856; p = 0.009).

3.6 Relationship between the number of risk factors considered (age > 65, CK ≥ 180, CD4+ T-cell counts <300) and progression to severe COVID-19

The number of risk factors considered (age > 65, CK ≥ 180, and CD4+ cell counts <300) was included in a Cox

Table 4: Treatment of COVID-19 patients within 14 days after admission

| Characteristics          | Total | No progression to severe COVID-19 | Progression to severe COVID-19 | p  |
|--------------------------|-------|----------------------------------|-------------------------------|----|
| LPV/r, n (%)             |       | 88                               | 74 (74.7)                      | 16 (82.4) | 0.711 |
| Yes                      | 88    | 25 (25.3)                        |                               | 3 (17.6) |      |
| No                       | 28    | 42 (42.4)                        | 4 (23.5)                       |      | 0.141 |
| Ribavirin, n (%)         |       | 46                               | 57 (57.6)                      | 13 (76.5) |      |
| Yes                      | 46    | 10 (10.1)                        | 6 (35.3)                       |      | 0.016 |
| No                       | 70    | 89 (89.9)                        | 11 (64.7)                      |      |      |
| Antibiotics, n (%)       |       | 16                               | 10 (10.1)                      | 6 (35.3) |      |
| Yes                      | 16    | 89 (89.9)                        | 11 (64.7)                      |      |      |
| No                       | 100   | 89 (89.9)                        | 11 (64.7)                      |      |      |
| TCM, n (%)               |       | 30                               | 26 (26.3)                      | 4 (23.5) | 1.000 |
| Yes                      | 30    | 73 (73.7)                        | 13 (76.5)                      |      |      |
| No                       | 86    | 57 (57.6)                        | 11 (64.7)                      |      |      |

LPV/r: lopinavir/ritonavir; TCM: traditional Chinese medicine.
### Table 5: Independent risk factors for progression to severe COVID-19

| Risk Factor                        | Total Progression to severe COVID-19 | p    | HR   | 95% CI          | p    | Adjusted HR | 95% CI          |
|------------------------------------|--------------------------------------|------|------|-----------------|------|-------------|-----------------|
| **Age**                            |                                      |      |      |                 |      |             |                 |
| <65 years                          | 103                                  | 10   | 1    | 1               |      | 1           | 1               |
| ≥65 years                          | 13                                   | 7    | <0.001 | 8.226 | 3.102–21.817 | <0.001 | 8.456       | 2.706–26.426 |
| **Symptoms at admission, n**       |                                      |      |      |                 |      |             |                 |
| No                                 | 10                                   | 1    |      | 1               |      | 1           | 1               |
| Yes                                | 106                                  | 16   | 0.637 | 1.628 | 0.216–12.274 |      |             |                 |
| **BMI**                            |                                      |      |      |                 |      |             |                 |
| <24                                | 55                                   | 6    |      | 1               |      | 1           | 1               |
| ≥24                                | 42                                   | 10   | 0.093 | 2.382 | 0.865–6.557  |      |             |                 |
| Unknown                            | 19                                   | 1    | 0.480 | 0.466 | 0.056–3.873  |      |             |                 |
| **Ribavirin, n**                   |                                      |      |      |                 |      |             |                 |
| Yes                                | 46                                   | 4    |      | 1               |      | 1           | 1               |
| No                                 | 70                                   | 13   | 0.141 | 2.323 | 0.757–7.125  |      |             |                 |
| **LPV/r, n**                       |                                      |      |      |                 |      |             |                 |
| Yes                                | 88                                   | 14   |      | 1               |      | 1           | 1               |
| No                                 | 28                                   | 3    | 0.476 | 1.574 | 0.452–5.477  |      |             |                 |
| **Antibiotics, n**                 |                                      |      |      |                 |      |             |                 |
| Yes                                | 100                                  | 11   | 0.006 | 3.996 | 1.476–10.821 |      |             |                 |
| No                                 | 16                                   | 6    | 1    | 1               |      | 1           | 1               |
| **Dyspnea, n**                     |                                      |      |      |                 |      |             |                 |
| Yes                                | 113                                  | 15   | 0.004 | 9.015 | 2.027–40.092 |      |             |                 |
| No                                 | 3                                    | 2    | 1    | 1               |      | 1           | 1               |
| **Diabetes, n**                    |                                      |      |      |                 |      |             |                 |
| Yes                                | 9                                    | 2    |      | 1               |      | 1           | 1               |
| No                                 | 107                                  | 15   | 0.477 | 0.585 | 0.134–2.561  |      |             |                 |
| **Hypertension, n**                |                                      |      |      |                 |      |             |                 |
| Yes                                | 14                                   | 3    |      | 1               |      | 1           | 1               |
| No                                 | 102                                  | 14   | 0.409 | 0.591 | 0.170–2.058  |      |             |                 |
| **Platelet count**                 |                                      |      |      |                 |      |             |                 |
| ≥100 × 10^9/L                      | 104                                  | 13   | 0.038 | 3.273 | 1.066–10.051 |      |             |                 |
| <100 × 10^9/L                      | 11                                   | 4    | 0.988 | 0         | 0     | 0           | 0               |
| Unknown                            | 1                                     | 0    |      | 1               |      | 1           | 1               |
| **C-reactive protein**             |                                      |      |      |                 |      |             |                 |
| <20 mg/L                           | 74                                   | 6    |      | 1               |      | 1           | 1               |
| ≥20 mg/L                           | 38                                   | 11   | 0.005 | 4.166 | 1.540–11.274 |      |             |                 |
| Unknown                            | 4                                     | 0    | 0.985 | 0         | 0     | 0           | 0               |
| **CK**                             |                                      |      |      |                 |      |             |                 |
| <180 U/L                           | 94                                   | 8    | 0.001 | 6.575 | 2.458–17.590 | 0.018 | 3.667       | 1.253–10.733 |
| ≥180 U/L                           | 18                                   | 8    |      | 1               |      | 1           | 1               |
| Unknown                            | 4                                     | 1    | 0.311 | 2.927 | 0.366–23.409 | 0.666 | 1.693       | 0.156–18.427 |
| **LDH**                            |                                      |      |      |                 |      |             |                 |
| <250 U/L                           | 87                                   | 7    |      | 1               |      | 1           | 1               |
| ≥250 U/L                           | 29                                   | 10   | 0.001 | 5.06  | 1.925–13.305 |      |             |                 |
| **AST**                            |                                      |      |      |                 |      |             |                 |
| <40 U/L                            | 100                                  | 12   |      | 1               |      | 1           | 1               |
| ≥40 U/L                            | 16                                   | 5    | 0.052 | 2.810 | 0.989–7.981  |      |             |                 |
| **Albumin**                        |                                      |      |      |                 |      |             |                 |
| ≥40 g/L                            | 87                                   | 9    |      | 1               |      | 1           | 1               |
| <40 g/L                            | 29                                   | 8    | 0.026 | 2.954 | 1.139–7.660  |      |             |                 |
| **Beta-2 microglobulin**           |                                      |      |      |                 |      |             |                 |
| <28 mg/L                           | 68                                   | 5    |      | 1               |      | 1           | 1               |
| ≥28 mg/L                           | 46                                   | 12   | 0.009 | 3.987 | 1.404–11.326 |      |             |                 |
| Unknown                            | 2                                     | 0    | 0.983 | 0         | 0     | 0           | 0               |
| **eGFR**                           |                                      |      |      |                 |      |             |                 |
| ≥100                               | 59                                   | 4    | 0.264 | 1     | 1           | 1               |
The consideration of one to two of our observed risk factors (HR = 10.644; 95% CI: 2.305–49.159; \( p = 0.002 \)) and all three risk factors (HR = 252.368; 95% CI: 24.390–2611.295; \( p < 0.001 \)) were found to be independently associated with progression to severe COVID-19 (Table 6) during 14 days of hospitalization after admission.

### Table 5: Continued

| Total Progression to severe COVID-19 | \( p \) | HR | 95% CI | \( p \) | Adjusted HR | 95% CI |
|-------------------------------------|--------|----|--------|--------|-------------|--------|
| <100                               | 0.020  | 3.793 | 1.236–11.638 |        |             |        |
| Unknown                             | 0.988  | 0 |  | 0 |             |        |
| PaO\(_2\)/FiO\(_2\) ≥400 mmHg      | 0.015  | 4.941 | 1.359–17.968 |        |             |        |
| PaO\(_2\)/FiO\(_2\) <400 mmHg      | 0.747  | 1.280 | 0.286–5.719 |        |             |        |
| Unknown                             | 0.005  | 0.467 | 0.052–4.177 | 0.461  | 0.397 | 0.034–4.626 |
| CD4\(^+\) T-cell counts ≥300/μL    | 0.028  | 3.022 | 1.125–8.118 |        |             |        |
| CD4\(^+\) T-cell counts <300/μL    | 0.170  | 0.230 | 0.028–1.872 |        |             |        |

**Table 6:** Independent risk factors for progression to severe COVID-19

| Number of factors (age > 65, CK ≥ 180, CD4\(^+\) cell counts <300) | Total Progression to severe COVID-19 | \( p \) | HR | 95% CI | \( p \) | Adjusted HR | 95% CI |
|---------------------------------------------------------------------|-------------------------------------|--------|----|--------|--------|-------------|--------|
| 0                                                                   | 50                                  | 2      | 1  |        |        |             |        |
| 1−2                                                                | 31                                  | 11     |    | 0.02   | 10.967 | 2.428–49.532 | 0.002  | 10.644 | 2.305–49.159 |
| 3                                                                  | 2                                   | 2      | <0.001 | 110.007 | 13.298–910.009 | <0.001 | 252.368 | 24.390–2611.295 |
| Unknown                                                             | 33                                  | 2      | 0.677 | 1.517 | 0.214–10.771 | 0.490  | 2.006  | 0.277–14.497  |

BM: body mass index; LPV/r: lopinavir/ritonavir; CK: creatine kinase; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; PaO\(_2\)/FiO\(_2\): partial arterial oxygen concentration/inspired oxygen fraction; eGFR: estimated glomerular filtration rate.

### 3.7 Fourteen-day cumulative survival without developing severe COVID-19

We analyzed the period from admission to developing severe COVID-19 over the duration of 14 days by the Kaplan–Meier method. We found that in patients aged 65 years or older, the rate of not progressing to severe COVID-19 at the end of 14 days was 46.2%, whereas in patients younger than 65 years, the rate of not progressing to severe COVID-19 at the end of 14 days was 90.2%, and the calculated difference in the rates of severe COVID-19 development between the two groups of patients was found to be significant in the statistical analysis.

**Table 6:** Independent risk factors for progression to severe COVID-19

| Number of factors (age > 65, CK ≥ 180, CD4\(^+\) cell counts <300) | Total Progression to severe COVID-19 | \( p \) | HR | 95% CI | \( p \) | Adjusted HR | 95% CI |
|---------------------------------------------------------------------|-------------------------------------|--------|----|--------|--------|-------------|--------|
| 0                                                                   | 50                                  | 2      | 1  |        |        |             |        |
| 1−2                                                                | 31                                  | 11     |    | 0.02   | 10.967 | 2.428–49.532 | 0.002  | 10.644 | 2.305–49.159 |
| 3                                                                  | 2                                   | 2      | <0.001 | 110.007 | 13.298–910.009 | <0.001 | 252.368 | 24.390–2611.295 |
| Unknown                                                             | 33                                  | 2      | 0.677 | 1.517 | 0.214–10.771 | 0.490  | 2.006  | 0.277–14.497  |

CK: creatine kinase; adjustment variables: symptoms at admission, body mass index, ribavirin use, lopinavir/ritonavir use, antibiotics use, dyspnea, comorbid diabetes, comorbid hypertension, platelet count, C-reactive protein, lactate dehydrogenase, aspartate aminotransferase, albumin, beta-2 microglobulin, estimated glomerular filtration rate, partial arterial oxygen concentration/inspired oxygen fraction, CD8\(^+\) cell counts.
The following findings were also observed in our analysis. In patients with a CK $\geq 180$ U/L, the rate of not progressing to severe COVID-19 at the end of 14 days was 55.6%, whereas in patients with a CK $< 180$ U/L, the rate of not progressing to severe COVID-19 at the end of 14 days was 91.5%, and again, there was a significant statistically calculated difference between these two rates of progression. In patients with CD4+ T-cell counts $< 300$ cells/µL, the rate of not progressing to severe COVID-19 at the end of 14 days was 53.8%, whereas in patients with CD4+ T-cell counts $\geq 300$ cells/µL, the rate of not progressing to severe COVID-19 at the end of 14 days was 83.2%, and the statistical difference between these two groups of patients was, again, computed to be significant (Figure 1).

### 4 Discussion

This study investigated the risk factors for progression to severe COVID-19 in patients diagnosed as mild or moderate COVID-19. The median age of patients developing severe COVID-19 during the hospitalized period of 14 days was significantly higher than that of those not developing severe COVID-19 (59 years [IQR, 50–70] vs 41 years [IQR, 35–54], $p < 0.001$), which concurs with the study results published previously [9].

In our study cohort of patients with milder COVID-19, we failed to observe a significant association between the presence of chronic diseases and the risk of disease progression, suggesting that the presence of chronic diseases may not necessarily contribute significantly to disease severity progression in such patients. Previous studies, however, have observed that some underlying chronic diseases, including hypertension and diabetes, may be risk factors for poor prognosis of COVID-19 [10–12]. The poor correlation of our results compared to that of other studies may be secondary to dissimilar study populations, differing sample sizes, and results obtained at different stages and locations of the COVID-19 outbreak, and warrants further investigation.

As outlined in Table 2, we did not observe any association between clinical symptoms and risk of disease progression. Frequently reported symptoms in our cohort of patients included fever, cough, sputum production, and fatigue. There were no significant differences in the proportion of patients progressing to severe COVID-19 between patients who exhibited the aforementioned symptoms and those who did not, suggesting that these symptoms were not sensitive indicators for disease progression in milder COVID-19 patients.

Compared with patients not developing severe COVID-19 during the period of 14 days after admission, patients progressing to severe COVID-19 during this period were more likely to have been administered antibiotics (10.1% vs 35.3%, $p = 0.016$). Antibiotics were used in this subgroup of patients to prevent or treat secondary nosocomial bacterial infections. Our result indicates that antibiotic use may not be useful in arresting disease progression in the natural history of COVID-19.

In the present study, we found that age $\geq 65$ years, CK $\geq 180$ U/L, and CD4+ cell counts $< 300$ cells/µL at admission were associated with disease progression.
during 14 days after hospital admission in patients with milder COVID-19. This result concurs with the previous study results in patients with severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19, in which older age was also found to be a risk factor for progression to severe disease [13–17]. Similarly, a recent study from Wuhan also found that laboratory cardiac injury diagnostic parameters, including CK, were associated with poor prognosis in COVID-19 patients [18]. This has also been observed in patients developing severe SARS and MERS, who also tended to have significantly higher CK levels (≥180 U/L) [19,20]. Secondary systemic myositis as a direct consequence of coronavirus infection may be a reasonable explanation for this increase in CK levels [21]. In addition, a decline in CK levels has been significantly associated with COVID-19 mRNA clearance ratios, which may indicate that this may be a good indicator for recovery of COVID-19 infection [22]. Wong et al. reported that T-lymphocyte subsets may be depleted early in the course of SARS and that low levels of CD4+ T-cell and CD8+ T-cell counts may be associated with poor clinical outcomes [23]. In the present study, we also observed that a CD4+ T-cell count <300 cells/µL was an independent risk factor for progression to severe COVID-19, suggesting that patients with milder COVID-19 develop CD4+ T-cell count depletion before significant disease progression, which was similar to the study conducted in Shanghai [17].

Our study has limitations. First, as a retrospective, observational study, it is inevitable that some data were incomplete, and this could possibly have led to biased effect estimate results. Second, the study period for data observation was only 14 days, which may not have been a long enough period to reflect actual disease progression during the course of the natural history of COVID-19. Third, the number of different factors included in our study for univariate and multivariate analyses may not have been comprehensive enough, and some potential risk factors may have been missed. Despite these limitations, our results may nevertheless be useful to indicate potential markers for possible disease progression in patients with mild to moderate COVID-19.

We observed that age ≥65 years, CK ≥ 180 U/L, and CD4+ T-cell counts <300 cells/µL at admission were risk factors associated with disease progression to severe COVID-19 during 14 days after admission. These factors may represent potential markers for possible disease progression in patients with milder COVID-19. Affording due attention to these risk factors may facilitate early identification of patients with the potential for progression to severe COVID-19 in the mild and moderate COVID-19 patient population. Patients with these risk factors will require close monitoring for potential COVID-19 disease progression during their hospital admission.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| ALT          | Alanine aminotransferase |
| AST          | Aspartate aminotransferase |
| BMI          | Body mass index |
| CK           | Creatine kinase |
| COVID-19     | Coronavirus disease 2019 |
| eGFR         | Estimated glomerular filtration rate |
| HR           | Hazard ratios |
| ICU          | Intensive care unit |
| IQR          | Interquartile range |
| LDH          | Lactate dehydrogenase |
| LPV/r        | Lopinavir/Ritonavir |
| MERS         | Middle east respiratory syndrome |
| PaO2         | Partial pressure of oxygen |
| PaO2/FiO2    | Partial arterial oxygen concentration/inspired oxygen faction |
| SARS         | Severe acute respiratory syndrome |
| SARS-CoV-2   | Severe acute respiratory syndrome coronavirus 2 |
| SD           | Standard deviation |
| TCM          | Traditional Chinese medicine |

**Acknowledgements**: This work was supported by the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control (No. cstc2020jscx-fyzxX0005). The funding body had no role in the collection, analysis and interpretation of data, the writing of the report, and the decision to submit for publication.

**Author contributions**: Y-KC, Y-HZ, and Y-YQ designed and executed this analysis. Y-KC and Y-HZ contributed to revising and finalizing the manuscript. HL, X-FY, and VH helped to revise the protocol. Y-QL, H-LL, S-KY, YW, and LZ contributed to data collection and management. All authors contributed to the refinement of the study protocol and have read and approved the final manuscript.

**Conflict of interest**: The authors declare no conflicts of interest.
References

[1] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–7.

[2] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.

[3] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

[4] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.

[5] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.

[6] Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744–8.

[7] Singhania N, Bansal S, Singhania G. An atypical presentation of novel coronavirus disease 2019 (COVID-19). Am J Med. 2020;133(7):e365–6. doi: 10.1016/j.ajmed.2020.03.026.

[8] Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020;382(20):e60.

[9] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. doi: 10.1001/jama.2020.1585.

[10] Alqahtani FY, Aleanzy F, Ali El Hadi Mohamed R, Alanazi MS, Mohamed N, Atrasheed MM, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect. 2019;147:e35. doi: 10.1017/S0950268818002923.

[11] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–61.

[12] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(1):e3319. doi: 10.1002/dmr.3319. [Epub ahead of print].

[13] Ahmed AE. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis. 2017;17(1):615.

[14] Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: a cohort study. Travel Med Infect Dis. 2019;29:48–50.

[15] Chen CF, Lee CH, Liu CY, Wang JH, Wang LM, Peng RP. Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. J Chin Med Assoc. 2005;68(1):4–10.

[16] Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A tool to early predict severe corona virus disease 2019 (COVID-19): a multicenter study using the risk nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 2020;71(15):833–40. doi: 10.1093/cid/ciaa443.

[17] Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6.

[18] Han H, Xie L, Liu R, Yang J, Liu F, Wu K, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020;92(7):819–23. doi: 10.1002/jmv.25809.

[19] Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–94.

[20] Al-Hameed F, Wahla AS, Siddiqui S, Ghabashi A, Al-Shomrani M, Al-Thaqafi A, et al. Characteristics and outcomes of middle east respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. J Intensive Care Med. 2016;31(5):344–8.

[21] Leung TW, Wong KS, Hui AC, To KF, Lai ST, Ng WF, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol. 2005;62(7):1113–7.

[22] Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599–606.

[23] Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326(7403):1358–62.